How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands

Vaccine

Volumn 27, Issue 37, 2009, Pages 5111-5119

  Coupé, Veerle M H ^a   de Melker, H E ^b   Snijders, Peter J F ^a   Meijer, Chris J L M ^a   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cervical cancer screening; HPV vaccination; Simulation model

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DNA DETERMINATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MONEY; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; MODELS, STATISTICAL; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 67650759130     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.043     Document Type: Article

References (53)

1. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003 Feb 6) 518-527
2. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 April (9518) (2006) 1247-1255
3. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 May (19) (2007) 1915-1927
4. Health Council of The Netherlands. Vaccination against cervical cancer. The Hague: Health Council of The Netherlands; 2008. Report no.: publication no. 2008/08.
5. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 July (29) (2007) 5399-5408
6. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 April (8) (2004) 604-615
7. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96 January (1) (2007) 143-150
8. Coupe V.M., Berkhof J., Bulkmans N.W., Snijders P.J., and Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in The Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98 February (3) (2008) 646-651
9. Franco E.L., and Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 3 June (3) (2007) 319-327
10. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 August (Suppl. 3) (2006) S3-78-S3/89
11. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 September (5) (2006) 1095-1101
12. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 November (9601) (2007) 1764-1772
13. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 October (16) (2007) 1589-1597
14. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla P.P., Del M.A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100 April (7) (2008) 492-501
15. Coupe V.M., van G.J., de Melker H.E., Snijders P.J., Meijer C.J., and Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer September (2008)
16. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9 May (5) (2008) 425-434
17. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 July (9172) (1999) 20-25
18. Nobbenhuis M.A., Meijer C.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Risse E.K., et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 84 March (6) (2001) 796-801
19. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.D., et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358 November (9295) (2001) 1782-1783
20. Zielinski G.D., Snijders P.J., Rozendaal L., Voorhorst F.J., Runsink A.P., de Schipper F.A., et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 195 October (3) (2001) 300-306
21. Berkhof J., Bulkmans N.W., Bleeker M.C., Bulk S., Snijders P.J., Voorhorst F.J., et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 15 July (7) (2006) 1268-1273
22. Bulk S., Berkhof J., Rozendaal L., Fransen Daalmeijer N.C., Gok M., de Schipper F.A., et al. The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer 96 April (8) (2007) 1234-1236
23. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 July (1) (2003) 101-105
24. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 January (1) (2003) 46-52
25. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12 April (2) (1993) 186-192
26. Bos A.B., van Ballegooijen M., van Oortmarssen G.J., van Marle M.E., Habbema J.D., and Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 75 1 (1997) 124-130
27. Briggs A., and Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13 April (4) (1998) 397-409
28. Ketting B.W. Surgical Treatment of Invasive Carcinoma of the Uterine Cervix (1981), University of Amsterdam, Amsterdam p. 154
29. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 96 May (9) (2007) 1419-1424
30. Berkhof J., de Bruijne M.C., Zielinski G.D., and Meijer C.J. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in The Netherlands. Int J Cancer 115 June (2) (2005) 268-275
31. Bulk S., Bulkmans N.W., Berkhof J., Rozendaal L., Boeke A.J., Verheijen R.H., et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 121 July (2) (2007) 361-367
32. Rozendaal L., Walboomers J.M., van der Linden J.C., Voorhorst F.J., Kenemans P., Helmerhorst T.J., et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 68 December (6) (1996) 766-769
33. Rozendaal L., Westerga J., van der Linden J.C., Walboomers J.M., Voorhorst F.J., Risse E.K., et al. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 53 August (8) (2000) 606-611
34. Gok M., Coupe V.M., Berkhof J., Verheijen R.H., Helmerhorst T.J., Hogewoning C.J., et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 104 February (2) (2007) 273-275
35. Bulk S., Berkhof J., Bulkmans N.W., Zielinski G.D., Rozendaal L., van Kemenade F.J., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94 January (1) (2006) 171-175
36. van den Akker-van Marle M.E., van Ballegooijen M., van Oortmarssen G.J., Boer R., and Habbema J.D. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 94 February (3) (2002) 193-204
37. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 March (3) (1997) 791-795
38. Snijders P.J., van den Brule A.J., and Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201 September (1) (2003) 1-6
39. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 May (18) (2002) 2372-2381
40. Berkhof J., de Bruijne M.C., Zielinski G.D., Bulkmans N.W., Rozendaal L., Snijders P.J., et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 118 7 (2006) 1759-1768
41. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema J.D.F. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Erasmus MC, Rottterdam, 2006.
42. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 June (9576) (2007) 1861-1868
43. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 May (19) (2007) 1928-1943
44. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 June (9580) (2007) 2161-2170
45. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 December (11) (2006) 1459-1466
46. Bulk S., van Kemenade F.J., Rozendaal L., and Meijer C.J. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 57 April (4) (2004) 388-393
47. Hesselink A.T., Bulkmans N.W., Berkhof J., Lorincz A.T., Meijer C.J., and Snijders P.J. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 44 October (10) (2006) 3680-3685
48. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124 February (3) (2009) 516-520
49. van Ballegooijen M., Koopmanschap M.A., Tjokrowardojo A.J., and van Oortmarssen G.J. Care and costs for advanced cervical cancer. Eur J Cancer 28A 10 (1992) 1703-1708
50. Franco E.L., Cuzick J., Hildesheim A., and de Sanjosé S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 August (Suppl. 3) (2006) S171-S177
51. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 August (Suppl. 10) (2008) K29-41
52. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 August (6) (2003) 781-789
53. Rogoza R.M., Ferko N., Bentley J., Meijer C.J.L.M., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine September (2008)